Baerenkraft Therapeutics is a pre-clinical stage pharmaceutical company developing novel therapies that harness and regulate the innate immune system to treat serious diseases with high unmet need. 

Baerenkraft's pipeline includes differentiated small molecules, with multiple assets advancing into first-in-human studies in 2026. Backed by a seasoned leadership team, Baerenkraft is advancing a pipeline across immunology & inflammation, metabolic, oncology, and rare diseases.